Johnson Investment Counsel Inc. decreased its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,792 shares of the pharmaceutical company’s stock after selling 515 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in GSK were worth $420,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Centerpoint Advisors LLC lifted its position in shares of GSK by 115.8% in the first quarter. Centerpoint Advisors LLC now owns 846 shares of the pharmaceutical company’s stock worth $30,000 after buying an additional 454 shares during the last quarter. GW&K Investment Management LLC boosted its position in GSK by 215.3% during the first quarter. GW&K Investment Management LLC now owns 1,110 shares of the pharmaceutical company’s stock worth $39,000 after purchasing an additional 758 shares during the period. SRS Capital Advisors Inc. grew its holdings in GSK by 52.9% during the first quarter. SRS Capital Advisors Inc. now owns 1,090 shares of the pharmaceutical company’s stock valued at $39,000 after purchasing an additional 377 shares during the last quarter. WealthPlan Investment Management LLC bought a new position in shares of GSK in the first quarter valued at approximately $42,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in shares of GSK by 61.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock worth $42,000 after buying an additional 368 shares during the last quarter. Institutional investors own 13.53% of the company’s stock.
GSK Price Performance
NYSE:GSK opened at $35.11 on Tuesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 0.95 and a quick ratio of 0.70. GSK plc has a one year low of $33.17 and a one year high of $39.74. The company has a fifty day moving average price of $36.05 and a 200 day moving average price of $35.44. The stock has a market cap of $71.89 billion, a P/E ratio of 9.44, a PEG ratio of 1.65 and a beta of 0.66.
GSK Cuts Dividend
Wall Street Analyst Weigh In
Separately, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 1st. Three analysts have rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, GSK presently has an average rating of “Hold” and an average target price of $1,553.75.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Five stocks we like better than GSK
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Safeguard your portfolio with these three bargain stocks
- Earnings Per Share Calculator: How to Calculate EPS
- Membership clubs gain leverage for the consumer rebound
- How to Invest in Renewable Energy
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.